Allogene Therapeutics, Inc. — Director's Dealing 2021

Aug 3, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Allogene Therapeutics, Inc. (ALLO)
CIK: 0001737287
Period of Report: 2021-07-30

Reporting Person: SATO VICKI L (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-07-30	Common Stock	A	19362	$0.00	Acquired	19362	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-07-30	Stock Option (Right to Buy)	$21.95	A	31692	Acquired	2031-07-30	Common Stock (31692)	Direct

Footnotes

F1: The shares subject to the stock option shall vest in a series of 36 successive equal monthly installments measured from the date of grant.